Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Drug Monitoring of Kinase Inhibitors and Study of Circulating Tumor DNA in Patients With Mutated BRAF Metastatic Cutaneous Melanoma and Treated With Anti-BRAF and Anti-MEK Kinase Inhibitors

NCT03416933 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.

NCT NCT03416933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03416933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Drug Monitoring of Kinase Inhibitors and Study of Circulating Tumor DNA in Patients With Mutated BRAF Metastatic Cutaneous Melanoma and Treated With Anti-BRAF and Anti-MEK Kinase Inhibitors
Lead sponsor
Institut de Cancérologie de Lorraine
Phase
Not applicable
Overall status
Completed
Start date
April 27, 2018
Completion date
June 17, 2022
Enrollment
35 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)